Representing Life Sciences Industry in Challenge against EU Extended Producer‑Responsibility Obligations under the UWWTD
T-158/25 – EFPIA v Parliament and Council (Eaux résiduaires urbaines II): Representing EFPIA and other leading life sciences trade associations in their challenge before the EU General Court to the extended producer‑responsibility obligations introduced by the recently revised Urban Wastewater Treatment Directive. We also represent several multinational pharmaceutical companies intervening in support of the action.
CJEU Preliminary Reference on Food Labelling and Plant-Based Product Names
C-438/23 – Protéines France and Others: Successfully acted in a landmark preliminary-reference case before the Court of Justice of the European Union concerning the compatibility of national bans on “meat-related” product names with Regulation (EU) 1169/2011.
EU Pharmaceutical Regulatory Litigation on New Active Substance and Orphan Medicinal Product Status
T-483/22 – Genzyme Europe v Commission: Represented Sanofi before the General Court of the European Union in an action for annulment challenging the Commission’s refusal to recognize a redesigned biological enzyme as a new active substance and its decision to withdraw orphan medicinal product status.
Challenge to EU/EFSA Prohibition on Aloe Vera in Food
T-189/21 – Aloe Vera of Europe v Commission: successfully represented Aloe Vera of Europe before the General Court of the European Union in an action for annulment challenging a Commission regulation prohibiting certain aloe-based food preparations.
Challenge to EU/EFSA Prohibitions on Botanical Preparations in Food
T-302/21 – Aboca and others v European Commission: successfully represented companies in challenging the EU/EFSA-wide prohibition on certain botanical preparations added to food in a precedent case under European fortified food rules. On appeal in Case C-38/25P
Challenges to EMA Decisions Requiring Disclosure of Clinical and Non‑Clinical Data
C‑389/13 P(R), C-175/18 P, T-729/15: Represented AbbVie, MSD, PTC Therapeutics and other innovative pharmaceutical companies and trade associations before the General Court and the Court of Justice of the EU in challenging the legality of the European Medicines Agency’s decisions to disclosure clinical and non-clinical data, including securing interim relief.
Challenge to EMA Decision Removing Orphan Status for a Pharmaceutical Product
T-329/16 – Bristol Myers Squibb v EMA: represented BMS in challenging the legality of a decision by the European Medicines Agency to remove a pharmaceutical product from the orphan register.
Precedent Litigation on the Legality of the Nutrition and Health Claims Regulation
T-296/12 – Health Food Manufacturers Association, Dutch Health Food Association and Others v European Commission and others: lead advocate in a precedent case challenging the legality of the Nutrition and Health Claims Regulation 1926/2006 and its implementing regulation 432/2012.